AKT1 and endometrial cancer: Effective blocking of PI3K-Akt and phospho p44/42 MAPK signalling pathways was achieved at 20 μM mifepristone in oral cancer cells, also reported in ovarian cancer, lung cancer [61,62], and endometrial cancer [63]; however, the latter showed the effectiveness of a mifepristone dose over 50 μM, which was too high for our cell lines and resulted in cell death.